ENTX Stock Summary and Trading Ideas (Entera Bio Ltd. - | NASDAQ:ENTX)

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Entera Bio Ltd. - trades on the NASDAQ stock market under the symbol ENTX.

As of May 8, 2024, ENTX stock price declined to $2.45 with 128,100 million shares trading.

ENTX has a beta of 0.99, meaning it tends to be less sensitive to market movements. ENTX has a correlation of 0.01 to the broad based SPY ETF.

ENTX has a market cap of $86.93 million. This is considered a Micro Cap stock.

In the last 3 years, ENTX stock traded as high as $8.68 and as low as $.47.

ENTX has outperformed the market in the last year with a price return of +198.7% while the SPY ETF gained +27.0%. ENTX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +231.8% and +10.4%, respectively, while the SPY returned +4.2% and +2.3%, respectively.

ENTX support price is $2.23 and resistance is $2.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENTX stock will trade within this expected range on the day.